

## ROZLYTREK - (100MG, 200MG ; Capsule)

<b>Generic Name</b>	ENTRECTINIB	<b>Innovator</b>	Genentech, Inc.
<b>Dosage</b>	100MG, 200MG ; Capsule	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	ROZLYTREK is a kinase inhibitor indicated for the treatment of: • Adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. • Adult and pediatric patients 12 years of age and older with solid tumors that: o have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion as detected by an FDA-approved test without a known acquired resistance mutation, o are metastatic or where surgical resection is likely to result in severe morbidity, and o have progressed following treatment or have no satisfactory alternative therapy.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.